Cairo hosts the International Conference on Breast Cancer, Gynecology and Immunology

Cairo has finally hosted the seventeenth International Conference on Breast, Gynecology and Immunology (BGICC 2025). The conference witnessed the presentation of the Tripoli study presented by MSD Egypt, and deals with the burden of the disease and the current treatments used for negative triple breast cancer (TNBC), a very aggressive type of breast cancer. This study supports continuous efforts to improve the care of cancer patients in the Arab region.

The results were presented during a press conference that included a group of oncology experts, which highlighted the importance and impact of detection and diagnosis in the early stages and effective treatment strategies for triple negative breast cancer in the Middle East and North Africa countries, with a special focus on the auxiliary therapeutic approach to improving results.
Dr. Hazem Abdel Samie, Director General of the MSD Egypt Group, stressed the importance of early detection and the role of cooperative efforts in facing the current challenges to care for cancer patients. He said: “Time is a decisive factor in the diagnosis of cancer, as it allows the early start of treatment before the disease spread. Regular and early can improve detection rates, which is vital to improving the chances of survival. “
He added: “We at MSD are committed to supporting cancer patients and enhancing treatment options in the region in cooperation with all the parties concerned in the health community.”
Professor Hamdi Abdel Azim, Professor of Oncology at Cairo University and head of the Cairo Oncology Center added: “The advanced disease requires innovation and improve access to care, and the results of the study can be used to direct future health care strategies to improve the results of negative triple breast cancer patients, especially in the less fortunate regions. The negative results of the advanced stages of the negative triple breast cancer highlight the need for innovative therapeutic strategies and increase access to effective treatments. Ensuring assistant chemotherapy and surgery in the Middle East and North Africa will be very important.
A group of oncology experts participated in the press conference, among them: Dr. Hisham Al -Ghazali, President of the BGICC Conference, Professor of Oncology and Director of the Research Center at Ain Shams University; Dr. Heba Al -Zawahiri, Professor of Oncology at the National Oncology Institute; Dr. Alaa Kandil, Professor of Clinical Oncology at Alexandria University; Dr. Marwan Ghosn, Director of the Cancer Center and Head of the Department of Hematology at Clemenceau Medical Hospital in Dubai. The session was moderated by Dr. Louay Qasim, Assistant Professor of Oncology and Radiotherapy at Cairo University.

Tripoli multi -state study
The Tripoli study is a multi -state realistic study that included a large number of new patients who were diagnosed in nine Arab countries (Egypt, Saudi Arabia, Oman, Qatar, Kuwait, Jordan, Morocco, Lebanon, Iraq). The study provides important visions on treatment and survival results for patients with negative triple breast cancer, which confirms the importance of early diagnosis. The results of the study are expected to be used to direct oncology practices and future cancer care strategies.

The most important results and visions from the study of Tripoli
The study emphasized the importance of early detection and interference in improving survival rates for negative triple breast cancer patients, and provided scientific evidence about optimal treatment strategies. The interventions are highlighted in the early stages, effective therapeutic systems, and therapeutic methods designated as main factors for improving patients ’results, especially in high -risk cases.

The study calls for urgent measures to implement strategies based on the transformational capabilities of early diagnosis, achieving a full pathological response (PCR), and adopting a multi -means approach to improving survival results for negative triple breast cancer patients, while paying special attention to the disadvantaged areas such as the Middle East and North region Africa. The study stresses the importance of cooperation between health care providers, policy makers and stakeholders to ensure fair and effective care for all negative triple breast cancer patients.

The main effects of study on the Middle East and North Africa region include:
• The importance of early detection in improving survival rates for negative triple breast cancer patients.
• The need to innovate and improve access to care to treat advanced disease.
• The necessity of cooperation between stakeholders to achieve justice in providing treatment.

Health economic analyzes were also conducted in many countries around the world to assess the economic impact to introduce a new treatment in its health systems. In Egypt, the effective cost analysis was conducted to understand the economic effects of treating highly risk negative breast cancer in its early stages, and the results showed that innovative treatments can meet the effective cost standards in Egypt when taking into account the quality of healthy life and the years of acquired life